Compare ADBE & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADBE | VRTX |
|---|---|---|
| Founded | 1982 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0B | 115.7B |
| IPO Year | 1986 | 1991 |
| Metric | ADBE | VRTX |
|---|---|---|
| Price | $334.24 | $451.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 24 |
| Target Price | $428.95 | ★ $497.77 |
| AVG Volume (30 Days) | ★ 4.4M | 1.3M |
| Earning Date | 12-10-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.11 | N/A |
| EPS | ★ 16.70 | 14.22 |
| Revenue | ★ $23,769,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $11.70 | $11.01 |
| Revenue Next Year | $9.21 | $8.74 |
| P/E Ratio | ★ $20.96 | $31.88 |
| Revenue Growth | ★ 10.53 | 10.33 |
| 52 Week Low | $311.59 | $362.50 |
| 52 Week High | $465.70 | $519.68 |
| Indicator | ADBE | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.22 | 53.64 |
| Support Level | $350.58 | $445.41 |
| Resistance Level | $356.68 | $464.44 |
| Average True Range (ATR) | 8.04 | 6.74 |
| MACD | -1.59 | -1.19 |
| Stochastic Oscillator | 8.37 | 39.12 |
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.